What is the ICD-10-CM code for a malignant neoplasm of overlapping sites of the right breast in a female patient who is estrogen-receptor positive?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ICD-10-CM Coding for Malignant Neoplasm of Overlapping Sites of Right Breast, Female, Estrogen Receptor Positive

The correct ICD-10-CM code is C50.811 for malignant neoplasm of overlapping sites of right breast, female, combined with Z17.0 for estrogen receptor positive status.

Primary Diagnosis Code

The anatomic site code C50.811 specifically identifies:

  • C50 = Malignant neoplasm of breast
  • .8 = Overlapping sites of breast (lesion involving two or more contiguous sites)
  • 11 = Right breast, female

This code captures the precise anatomic location when the tumor involves multiple overlapping areas of the right breast that cannot be classified to a single specific site (such as upper outer quadrant, lower inner quadrant, etc.).

Required Additional Code for Receptor Status

Z17.0 must be added as a secondary code to document estrogen receptor positive status. This is critical because:

  • Receptor status directly impacts treatment decisions and prognosis
  • It is required for accurate staging under the AJCC 8th edition TNM system, which incorporates biological markers 1
  • Estrogen receptor positivity indicates eligibility for endocrine therapy, which reduces recurrence odds by 41% and death odds by 31% 2

Complete Coding Structure

Primary code: C50.811 (Malignant neoplasm of overlapping sites of right breast, female)

Secondary code: Z17.0 (Estrogen receptor positive status [ER+])

Clinical Context

The estrogen receptor positive designation is essential for treatment planning. For ER-positive breast cancers, endocrine therapy is the cornerstone of adjuvant treatment regardless of age, lymph node status, or whether chemotherapy is administered 2. The specific treatment approach varies based on menopausal status, with options including tamoxifen, aromatase inhibitors, and ovarian function suppression in premenopausal women 3.

Common Coding Pitfalls to Avoid

  • Do not use C50.9 (unspecified site of breast) when overlapping sites are documented
  • Do not omit the laterality digit (the final "1" indicating right breast)
  • Do not forget Z17.0 - receptor status is not optional; it's a required component of complete cancer coding
  • Do not use C54.x codes - these are for uterine/endometrial malignancies, not breast 4

The combination of these two codes provides complete documentation for billing, registry reporting, and clinical decision support systems.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.